Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Global disparities in hearing care services and infrastructure: findings from a 47-country international provider survey
Zalaquett, Nader G., Frost, Robert, Stucki, Brenton R., Aggarwal, Komal, Useche, Mateo, Jaffer, Ali F. , Mokoh, Lilian Wairimu, Xu, Mary Jue , Patterson, Rolvix H., Chung, Sarah, Lageju, Nabin , Edouard, Amani , Sagun, Joyce Rodvie, Patterson, Rolvix H. , Patterson, Rolvix H , Zalaquett, Nader , Frost, Robert, Stucki, Brenton, Aggarwal, Komal , Useche, Mateo , Sagun, Joyce Rodvie, Waterworth, Christopher J.

Mayo Clinic

International Journal of Audiology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-14

10.1080/14992027.2026.2687005 | PMID 42421334 Get It

Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331
Casey, Dana L. , Renfro, Lindsay A., Wu, Yue , McCarten, Kathleen, Pei, Qinglin , Milgrom, Sarah A., Cho, Steve, Keller, Frank G., Punnett, Angela, Kelly, Kara M., Castellino, Sharon M., Hoppe, Bradford S , Casey, Dana L , McCarten, Kathleen M. , Belsky, Jennifer A. , Keller, Frank G. , Punnett, Angela , Hodgson, David , Hoppe, Bradford S. , Kelly, Kara M. , Castellino, Sharon M.

Mayo Clinic

British Journal of Haematology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70625 | PMID 42419755 Get It

Summary Outcomes for high‐risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra‐nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2–21 years with high‐risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE‐PC) versus Bv‐AVEPC. Patients with stage IV disease, determined by protocol‐defined and centrally reviewed Positron Emission Tomography ‐ Computed Tomography (PET‐CT), were identified. Baseline characteristics and progression‐free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE‐PC and 167 (49%) Bv‐AVEPC. PFS was highest with lung‐only involvement (4‐year PFS 88.6%) and lowest with bone marrow‐only involvement (4‐year PFS 71.9%). Compared to ABVE‐PC, Bv‐AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33–0.85) and in the lung‐only and bone‐only subgroups. However, no PFS benefit was observed in those with bone marrow‐only involvement. Among paediatric patients with stage IV cHL, Bv‐AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.
Patient-Centered Approach to Surgical Prevention of Ovarian Cancer
Lu, Karen H., Chisholm, Gary B. , Peterson, C., Roche, Kara Long , Bakkum-Gamez, Jamie, Feltmate, Colleen, Kim, Sarah, Hagemann, Andrea R. , Carter, Jeanne , Hickey, Martha, Crase, Jamie , Gavin, K, Polinsky, Deborah , D'Andrea, AD, Lu, Karen H. , Norquist, Barbara M. , Bakkum‐Gamez, Jamie N. , Romero, Iris L. , Feltmate, Colleen M. , Levine, Douglas A. , Hickey, Martha , Gavin, Kathleen , D’Andrea, Alan D. , Nebgen, Denise R. , Swisher, Elizabeth M.

Mayo Clinic

JAMA Network Open | July 7, 2026 | Volume: 9 | Issue: 7 | Pages: e2622026

10.1001/jamanetworkopen.2026.22026 | PMID 42412428 Get It

Importance Risk-reducing salpingo-oophorectomy (RRSO) is an effective option to prevent ovarian cancer in high-risk individuals, but adverse effects from premature menopause are a barrier to uptake. Interval salpingectomy with delayed oophorectomy (ISDO) may be an effective alternative. Objective To evaluate the association of ISDO vs RRSO and sexual function and menopausal symptoms. Design, Setting, and Participants This prospective, multicenter, nonrandomized (patient preference) clinical trial was performed among Women Choosing Surgical Prevention participants with a pathogenic or likely pathogenic germline variant conferring an increased risk for ovarian cancer. Patients from 9 US centers were enrolled from June 2, 2016, to October 28, 2020; chose ISDO or RRSO; and were followed up for 24 months. The analysis was performed on November 13, 2024. Interventions Participant-selected RRSO or ISDO. Main Outcomes and Measures Changes in sexual function and menopausal symptoms from baseline to 6, 12, and 24 months. Inverse probability weighting was applied to achieve covariate balance across groups. Results The analytic sample included 334 female participants (mean [95% CI] age at consent, 39.2 [38.7-.9.7] years) who underwent RRSO (n = 165) or ISDO (n = 169) and completed 6-month questionnaires. Significantly more participants experienced clinically meaningful worsening of sexual function at 6 months compared with baseline after RRSO vs ISDO (33.1% [39 of 118] vs 16.8% [17 of 101], respectively; odds ratio, 2.00 [95% CI, 1.20-3.35]) and at 12 months (39.2% [38 of 97] vs 18.3% [17 of 93], respectively; odds ratio, 1.69 [95% CI, 1.09-2.63]). This finding was no longer significant at 24 months. When restricted to the RRSO group who took hormone replacement therapy, there was no significant worsening of total sexual function scores or menopausal symptoms compared with baseline. No interval ovarian cancers were reported. Conclusions and Relevance This nonrandomized clinical trial comparing RRSO with ISDO found that ISDO was less likely to impair sexual function, which addresses an important barrier to surgical prevention in high-risk patients in premenopause. After RRSO, use of hormone replacement therapy mitigated menopausal symptoms and prevented decline in sexual function. More information is needed about the safety of ISDO. Trial Registration ClinicalTrials.gov Identifier: NCT02760849
Targeted proteomics of postmortem human brain reveals neurobiologic heterogeneity in Alzheimer’s disease using NULISA technology
Dunlop, Sara , Lincoln, Sarah, Graff-Radford, Neill, Lachner, Christian , Tranovich, Jessica F., Reichard, R. Ross, Dickson, DW, Petersen, Ronald C, Boeve, Bradley F, Nguyen, Aivi, Grinberg, Lea T, Graff-radford, Jonathan, Algeciras-Schimnich, Alicia, Murray, Melissa E , Peng, Zhongwei , Graff‐Radford, Neill R. , Day, Gregory S. , Reichard, R. Ross , Dickson, Dennis W. , Petersen, Ronald C. , Boeve, Bradley F. , Nguyen, Aivi, Grinberg, Lea T. , Graff‐Radford, Jonathan , Algeciras‐Schimnich, Alicia , Murray, Melissa E.

Mayo Clinic

No container title available | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.01.735558 | PMID 42465448 Get It

Abstract Background Alzheimer’s disease (AD) is clinicopathologically heterogeneous. A proportion of patients living with AD present clinically at a younger onset of cognitive symptoms before 65 years old and/or non-amnestic clinical syndromes. Neuropathologically, corticolimbic distribution of neurofibrillary tangle pathology occurs on a continuum with some cases having greater cortical tau pathology relative to limbic regions and others with relatively restricted accumulation in limbic structures. These patterns of corticolimbic tangle distribution are associated with clinical presentation and age at onset. This study sought to examine protein expression differences across the spectrum of clinicopathologic heterogeneity using the NULISA targeted proteomics platform. Methods A series of thirteen neuropathologically diagnosed AD cases from Mayo Clinic prospectively followed research studies were selected to reflect heterogeneity of clinical syndromes and corticolimbic distribution of tangle pathology. Frozen postmortem brain tissue samples were isolated from inferior parietal cortex and homogenized in RIPA buffer for analysis using Alamar Biosciences’ NULISA CNS disease 120 panel. Applying a conservative detection threshold of 75% level of detection for the novel application of NULISA in human brain, we evaluated levels of 69 of 129 protein targets across samples. We examined associations between age at onset cognitive symptoms and corticolimbic distribution of tangles (CLix) separately with individual protein targets using linear regression analysis. Results AD cases with a younger age at onset had higher measured levels of ubiquitin, while older age was associated with higher levels of total tau, CRH, and NPTX2. Investigations of corticolimbic heterogeneity revealed AD cases with lower CLix score (i.e., cortical predominant distribution of tau) had higher measured p-tau181, p-tau231, ubiquitin, and p62. AD cases with higher CLix (i.e., relative cortical sparing) had higher levels of total tau, CRH, NPTX2, MDH1, and HBA1. Brain-derived total tau consistently showed a stronger association in both models. Conclusion This work demonstrates the utility of postmortem proteomics for investigating biomarkers associated with AD clinicopathologic heterogeneity. We observed proteomic differences in synapse integrity, tau post-translational modification, and ubiquitination associated with age at symptomatic onset and corticolimbic distribution of tangle pathology.
Interleukin-17A mediates cardiorenal injury in oxalate nephropathy
Wimmer, Moritz I. , Reichel, Martin , Thiele, Arne , Yarritu, Alex , Rauch, Ariana , Anandakumar, Harithaa , Goetz, Luisa Hernandez , Lesker, Till Robin , Potapenko, Olena , Gebremedhin, Natnael , Anders, W , Contreras, Sarah V. Liévano , Höppe, Bernd , Schiattarella, Gabriele G. , Holle, Johannes , Knauf, Felix , Wilck, Nicola , Bartolomaeus, Hendrik , Hernández Götz, Luisa , Lesker, Till R , Anders, Wibke , Liévano Contreras, Sarah V , Wang, Rongling , Behrens, Felix , Hoppe, Bernd , Nonn, Olivia , Schiattarella, Gabriele G. , Schaefer, Franz , Holle, Johannes , Strowig, Till , Zernecke, Alma , Eckardt, Kai-Uwe , Knauf, Felix , Wilck, Nicola , Bartolomaeus, Hendrik , Potapenko, Olena

Mayo Clinic

Cardiovascular Research | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cvr/cvag158 | PMID 42417540 Get It

Abstract Aims Cardiovascular disease (CVD) is the leading cause of mortality in chronic kidney disease (CKD). While CKD is known to give rise to systemic inflammation, its inciting factors remain poorly defined. Oxalate, long implicated in rare genetic kidney disorders, accumulates with decreased kidney function and has emerged as a driver of inflammation and independent risk factor for CVD. Here, we investigate the immunological mechanisms linking oxalate nephropathy to systemic inflammation, cardiac damage and kidney injury. Methods and results Oxalate nephropathy was induced in C57BL6/N mice through an oxalate-enriched diet. Oxalate induced systemic immune activation, renal fibrosis, and adverse cardiac remodelling, including pulmonary congestion with systolic and diastolic dysfunction. Flow cytometry analysis identified interleukin (IL)-17A as a dominant inflammatory effector, with expansion of Th17 and Th17-like Treg in the kidney, intestine, and spleen. Bulk mRNA sequencing confirmed these findings in kidney and heart. In line, plasma IL-17A was increased in oxalate-fed mice. Confirming the oxalate-IL-17A relationship, plasma IL-17A was elevated in patients with primary hyperoxaluria. Gut microbiome analysis by 16S amplicon sequencing showed only mild oxalate-induced alterations in mice. However, soluble oxalate directly enhanced Th17 polarization and disrupted mitochondrial respiration in vitro. In vivo, antibody-mediated IL-17A blockade improved kidney function, cardiac fibrosis, reduced neutrophil infiltration, and partially restored cardiac function in oxalate-fed mice. Conclusion Our study identifies oxalate as a systemic immunometabolic stressor and IL-17A as a central mediator of oxalate-induced cardiorenal injury. These findings establish the oxalate-IL-17A axis as a mechanistic link between CKD and CVD and suggest IL-17A inhibition as a potential therapeutic strategy to reduce cardiovascular damage in CKD.
Ventilator-Associated Pneumonia According to Chlorhexidine Oral Care Exposure in Patients With New Tracheostomy
Thompson, Hailey, Neiβ, A, Kooda, Kirstin, Shah, Aditya, Chalmers, Sarah, Cole, Kristin, Vollmer, Nicholas, Nei, Andrea, Kooda, Kirstin

Mayo Clinic

American Journal of Critical Care | July 3, 2026 | Volume: 35 | Issue: 4 | Pages: 289-297

10.4037/ajcc2026305 | PMID 42380032 Get It

Background Chlorhexidine is commonly used in prevention bundles for ventilator-associated pneumonia. Results for use of chlorhexidine in critically ill patients requiring mechanical ventilation via an endotracheal tube are mixed, and data for patients using a tracheostomy are lacking. Objectives To assess the risk for ventilator-associated pneumonia according to chlorhexidine exposure in patients requiring a new tracheostomy for mechanical ventilation. Methods This single-center, retrospective cohort study compared the development of ventilator-associated pneumonia according to chlorhexidine exposure in adult intensive care unit patients requiring new tracheostomy at a large academic medical center. Adults who received a new tracheostomy and required ventilator support for at least 48 hours were included. Patients treated for pneumonia at the time of tracheostomy or who met additional exclusion criteria were excluded. Results Of 235 patients who met the inclusion criteria, 203 received chlorhexidine and 32 did not. The cohort was predominantly White, male, and admitted to a surgical intensive care unit. Incidence of ventilator-associated pneumonia did not differ significantly between patients exposed or not to chlorhexidine (by 30 days, 32.5% vs 35.7%, P = .87). Time to development of ventilator-associated pneumonia also did not differ significantly between patients exposed or not (9 vs 12 days, respectively, P = .34). Conclusions Chlorhexidine exposure was not associated with a difference in the incidence of or time to ventilator-associated pneumonia after new tracheostomy. Further study is needed on the role of chlorhexidine in preventing ventilator-associated pneumonia after a new tracheostomy.
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
Gaballa, Mahmoud R. , Julian, Kelley , Afrough, Aimaz , Hansen, Doris K. , Goel, Utkarsh , Corraes, Andre De Menezes Silva, Dima, Danai , Rana, Masooma , Hosoya, Hitomi , Mikkilineni, Lekha , Fogel, Lindsay , Raza, Shahzad, Zanwar, Saurabh , Sannareddy, Aishwarya, Borogovac, Azra , Green, Kimberly M , Biran, Noa, Shune, Leyla, Ouchveridze, Evguenia, DeJarnette, Shaun, Ferreri, Christopher J, Richards, Tiffany, Bal, Susan , Ye, Jing Christine, Shain, Kenneth H. , Harada, Ken , Avila, Gabriel De, Voorhees, Peter, Khouri, Jack , Sidana, Surbhi , Lin, Yi, Patel, Krina K. , Sborov, Douglas W. , Gaballa, Mahmoud , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Zanwar, Saurabh S , Borogovac, Azra , Davis, James A , Green, Kimberly , Zolotov, Eli , Herr, Megan M. , Abid, Muhammad Bilal , Bal, Susan , Ali, Hossam M , Kaur, Gurbakhash , Shain, Kenneth H , Castaneda Puglianini, Omar , Hassan, Hamza , Anderson, Larry D , Khouri, Jack , Sidana, Surbhi , Portuguese, Andrew J , Janakiram, Murali , Lee, Hans C , Patel, Krina , Sborov, Douglas W , Dima, Danai , Hosoya, Hitomi , Rana, Masooma S , Julian, Kelley L , Hansen, Doris K , Corraes, Andre De Menezes Silva , Raza, Shahzad , Banerjee, Rahul , Pasvolsky, Oren , Sannareddy, Aishwarya , Davis, James A. , Biran, Noa , Zolotov, Eli , Shune, Leyla , Atrash, Shebli , Ferreri, Christopher J. , Richards, Tiffany, Abid, Muhammad Bilal , Ali, Hossam M. , Ye, Jing Christine, Richard, Shambavi , Kaur, Gurbakhash , Puglianini, Omar Castañeda , Rossi, Adriana , Hassan, Hamza , Anderson, Larry D. , Voorhees, Peter M. , Portuguese, Andrew J. , Janakiram, Murali , Lee, Hans C. , Grajales‐Cruz, Ariel

Mayo Clinic

Blood Advances | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020826 | PMID 42392158 Get It

Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as 'active' (≥5% circulating plasma cells within 30 days of BsAb initiation) or 'historical'. In a heavily pretreated population, patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging therapy to CAR-T (Tal Bridge, 11%). Cytokine release syndrome (CRS) was grade 1-2 in 56% and grade 3-4 in 4%, whereas neurotoxicity was grade 1-2 in 16% and grade 3-4 in 5%. Among 110 evaluable patients, the overall response rate (ORR) was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS of 1.2 and 1.6 months and mOS of 8.1 and 3.6 months, respectively (P=0.007, P=0.023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12.2 months versus 0.7/1.4 months with teclistamab and 1.0/3.1 months with elranatamab, respectively (P<0.001, P=0.002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were safe in PCL, with talquetamab showing superior outcomes compared with BCMA-directed BsAbs.
Procedure Training Workshop: Enhancing Resident Experience and Enthusiasm for Ultrasound-guided Bedside Procedures
Zheng, Cynthia , Abubeker, Ibrahim Y. , Freeman, Sarah , Freeman, Sarah R

Mayo Clinic

Journal of Brown Hospital Medicine | July 1, 2026 | Volume: 5 | Issue: 3 | Pages: No page available

10.56305/001c.162045 | PMID 42405368 Get It

Background Accreditation Council for Graduate Medical Education (ACGME) requires internal medicine (IM) residents to perform procedures considered “essential for the area of practice.” However, no guidelines or best practices exist for teaching these skills. To address this gap, a procedure training workshop (PTW) was developed. Methods IM residents attended a PTW where they practiced paracenteses, lumbar punctures (LPs), and central venous catheter (CVC) placement on ultrasound-compatible task trainers. The PTW was assessed using pre- and post-session tests and surveys. To evaluate translation into clinical practice, procedure volume, success rates, and immediate complications were tracked. Results Following implementation of the PTW, resident knowledge assessment scores increased from 67.4% to 84.1% (p < 0.001). More residents reported feeling “well-prepared” to perform or “teach others” procedures (CVC 69% from 31%, p < 0.01; LP 71% from 8%, p < 0.05; paracentesis 80% from 28%, p < 0.05) and able to perform all steps without assistance or model (CVC 54% from 28%; LP 49% from 17%, p < 0.01; paracentesis 66% from 25%, p < 0.01). Paracenteses increased from 71 (2020) to 119 (2021) to 143 (2024), while LPs increased from 87 (2020) to 156 (2021) to 135 (2024). Success rates remained stable across procedures: paracentesis (91.5% to 94.1% to 93.7%), LP (58.6% to 55.8% to 52.6%), and CVC placement (95.5% to 97.6% to 94.9%). Conclusions PTW is a valuable half-day session that equips early residents with essential procedural knowledge and hands-on practice that translates into sustained increases in bedside procedure volume.
Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE
Crew, Katherine D. , Arnold, Kathryn B. , Dzingle, Sam, Michel, Alissa, DeLucie, Michael, Law, Cynthia W., Pruthi, Sandhya , Leon, Ana C Sandoval, Shirley, Rachel, Perdekamp, Maria T Grosse, Colonna, Sarah V, Krisher, Stacy L, King, Tari A. , Yee, Lisa D. , Braun-Inglis, Christa, Mangino, Debra A. , Wisinski, Kari B. , DeYoung, Claudia A, Ross, Masey, Floyd, Justin D., Kaster, Andrea, VanderWalde, Lindi, Saphner, Thomas J. , Zarwan, Corrine, Lo, Shelly, Graham, Cathy, Conlin, Alison, Yost, K. , Agnese, Doreen M, Jernigan, Cheryl, Neuhouser, Marian L, Arun, Banu, Pruthi, Sandhya , Anderson, Garnet L. , Michel, Alissa , DeLucie, M. T., Sandoval-Leon, Ana Cristina , Shirley, Rachel, Perdekamp, Maria T. Grosse, Colonna, Sarah V. , Krisher, Stacy, Ballinger, Tarah Jean , Braun‐Inglis, Christa , Ross, Masey, Graham, Cathy Lynne , Yost, Kathleen J. , Agnese, Doreen Marie , Hershman, Dawn L. , Zell, Jason A. , Kukafka, Rita

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag216 | PMID 42391096 Get It

Abstract Background Breast cancer chemoprevention is underutilized among high-risk women. We examined whether decision support could increase informed decision making. Methods We conducted a cluster randomized controlled trial to evaluate the effect of a patient-facing decision aid (RealRisks) and provider tool (BNAV) compared with standard education on the number of women with high-risk breast lesions making informed choices. Questionnaires were administered at baseline and 6 and 12 months. The primary outcome was chemoprevention informed choice (defined as adequate knowledge and attitudes congruent with decision) at 6 months. Secondary endpoints included breast cancer risk perceptions, worry, chemoprevention knowledge, decision conflict, and chemoprevention decision. Results Across 31 randomized sites, we enrolled 210 providers, who were primarily breast health specialists. Of these, 24 sites (14 intervention, 10 control) enrolled 412 patients. Among 287 patients evaluable for the primary outcome, there were no statistically significant differences in informed choice between the intervention and control arms at 6 months (35% vs 27%, respectively; P = .20) and 12 months (37% vs 25%, respectively; P = .05). At 6 months, women in the intervention compared with control arm were more likely to have accurate breast cancer risk perceptions (31% vs 21%, respectively; P = .03) and adequate chemoprevention knowledge (33% vs 23%, respectively; P = .04). At 12 months, 52% of women in the control and 50% in the intervention arm self-reported initiating chemoprevention. Conclusion Decision support led to modest improvements in accurate risk perceptions and chemoprevention knowledge but not informed choice. Relatively high chemoprevention uptake was achieved among women with high-risk breast lesions managed mainly by breast health specialists. Trial Registration NCT04496739, https://clinicaltrials.gov/study/NCT04496739?cond=NCT04496739&viewType=Card&rank=1